Close Menu

NEW YORK (GenomeWeb) – Eisai subsidiary Morphotek today announced a collaboration and licensing agreement with Fujirebio Diagnostics to validate and commercialize the CA125 II assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.